Dataset Information

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China.

ABSTRACT: Objective:To investigate the frequency and prognostic role of the human epidermal growth factor receptor 2 gene (HER2) and BRAF V600E gene mutation in Chinese patients with colorectal cancer (CRC). Methods:Clinicopathological and survival information from 480 patients with stage I-III CRC were reviewed and recorded. HER2 amplification was analyzed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), BRAF V600E mutation was tested by IHC and Sanger sequencing. The relationship between HER2 and BRAF V600E mutation status and clinicopathological characteristics and outcomes were determined. Results:The amplification of HER2 and BRAF V600E mutation were identified in 27 of 480 (5.63%) and 19 of 480 (3.96%) CRC patients, respectively. HER2 amplification significantly correlated with greater bowel wall invasion (P = 0.041) and more advanced TNM stage (I vs. II vs. III; 0 vs 5.78% vs. 7.41%, P = 0.013). Patients suffering from tumors with poor differentiation had a higher incidence rate of BRAF V600E mutation than those with moderate/well differentiation (7.77% vs 2.92%, P = 0.04). HER2 amplification was an independent prognostic factor for worse disease-free survival (DFS) (HR = 2.53, 95% CI: 1.21-5.30, P = 0.014). Conclusion:The prevalence of HER2 amplification and BRAF V600E mutation in stage I-III CRC patients in Chinese was 6% and 4%, respectively, and HER2 amplification appeared to be associated with a worse DFS. More comprehensive molecular classification and survival analysis are needed to validate our findings.

SUBMITTER: Zhang X

PROVIDER: S-EPMC7023828 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

<i>HER2</i> and <i>BRAF</i> mutation in colorectal cancer patients: a retrospective study in Eastern China.

Zhang Xiangyan X Wu Jie J Wang Lili L Zhao Han H Li Hong H Duan Yuhe Y Li Yujun Y Xu Ping P Ran Wenwen W Xing Xiaoming X

PeerJ 20200212

<h4>Objective</h4>To investigate the frequency and prognostic role of the human epidermal growth factor receptor 2 gene (<i>HER2</i>) and <i>BRAF</i> V600E gene mutation in Chinese patients with colorectal cancer (CRC).<h4>Methods</h4>Clinicopathological and survival information from 480 patients with stage I-III CRC were reviewed and recorded. <i>HER2</i> amplification was analyzed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), <i>BRAF</i> V600E mutation was tested ...[more]

PMID: 32095377

Similar Datasets

Project description:BackgroundPatients with V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E-mutated advanced colorectal cancer (CRC) have a poor prognosis, and treatment options that can improve outcome are still under investigation. The purpose of this study was to discuss the differences of overall survival (OS) and progression-free survival (PFS) between patients with BRAF V600E-mutated advanced CRC who were treated with chemotherapy alone and chemotherapy combined with targeted therapy in advanced first-line therapy.MethodsGrouping of 61 patients according to first-line treatment regimen (chemotherapy alone/chemotherapy combined with bevacizumab). Kaplan-Meier method and log-rank test were used to compare OS and PFS. Cox proportional hazards regression model was used to measure the risk of first-line medication therapies while correcting for confounding factors that may affect PFS and OS.ResultsThere was no significant difference in OS between patients treated with chemotherapy alone and those treated with chemotherapy combined with bevacizumab (P = 0.93; HR, 1.027; 95% CI, 0.555-1.901). Likewise, there was no significant difference in PFS between the two groups (P = 0.29; HR, 0.734; 95% CI, 0.413-1.304). Subgroup analysis showed that OS and PFS of different treatment regimens were not significantly different among subgroups. Multivariate analysis suggested that surgical treatment of primary tumor (P = 0.001; HR, 0.326; 95% CI, 0.169-0.631) and presence of liver metastasis (P = 0.009; HR, 2.399; 95% CI, 1.242-4.635) may serve as independent prognostic indicators in patients with BRAF-mutated advanced CRC. Surgical treatment of the primary tumor (P = 0.041; HR, 0.523; 95% CI, 0.280-0.974) was significantly associated with PFS too.ConclusionFor patients with BRAF V600E-mutated advanced CRC, chemotherapy alone did not differ significantly in OS and PFS compared with chemotherapy + bevacizumab for advanced first-line therapy. Chemotherapy combined with targeted therapy did not render a survival benefit to these patients, demonstrating that the importance of developing new treatment options for this population.

Dataset Information

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China.

Publications

<i>HER2</i> and <i>BRAF</i> mutation in colorectal cancer patients: a retrospective study in Eastern China.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets